Abstract
Introduction
Although the pathophysiology of sepsis has been extensively studied, the disease remains a common cause of death in the critically ill patient. It thus remains one of the most pressing clinical and economic problems of modern medicine. A vast amount of inflammatory mediators have been identified as key factors in driving sepsis. Therapeutic agents designed to target these mediators have so far failed to demonstrate significant clinical benefit.
Methods
Clinical trials are the standard for assessing safety and efficacy of novel agents but are made difficult by the heterogeneous nature of septic patients. This review aims to highlight the complex nature of sepsis and the inherent difficulties encountered in designing clinical trials in these patients. The major factors contributing to the difficulties in improving internal and external validity will be discussed with the aim of guiding future study design.
Conclusions
The design of clinical trials on the septic patient remains a challenge. Methodology must be rigorous if seemingly positive clinical trials which are widely implemented are later discredited as a result of poor study design. Many lessons can be learnt from the study design of the PROWESS trial, however there remains room for improvement. This review serves as a stimulus and guide in motivating much needed high quality clinical trials in sepsis.
Similar content being viewed by others
References
Vincent JL, Sakr Y, Sprung CL et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34(2):344–353
Harrison DA, Welch CA, Eddleston JM (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 10(2):R42
Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 34:17–60
Levy MM, Dellinger RP, Townsend SR et al (2010) Surviving sepsis campaign: the Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 38:367–374
Opal SM (1995) Lessons learned from clinical trials of sepsis. J Endotoxin Res 2:221–226
Vincent JL (2004) Evidence-based medicine in the ICU: important advances and limitations. Chest 12(2):592–600
Vincent JL, Sun Q, Dubois MJ (2002) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34:1084–1093
Fisher CJ, Agosti JM Jr, Opal SM et al (1996) Treatment of septic shock by tumour necrosis factor receptor: Fc fusion protein. N Engl JMed 334:1697–1702
Annane D (2000) Effects of the combination of hydrocortisone (HC)-fludrocortisone (FC) on mortality in septic shock. Crit Care Med 28:A63
van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367
Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Sprung CL, Annane D, Keh D et al (2008) Corticus study group: hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
Brunkhorst FM, Engel C, Bloos F et al (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139
Rowan KM, Kerr JH, Major E, Mc Pherson K, Short A, Vessey MP (1993) Intensive care society APACHE II study in Britain and Ireland II: outcome comparisons of intensive care units after adjustment for case mix by the American APACHE II method. BMJ 307:977–981
Sprung CL, Eidelman LA, Pizov R et al (1997) Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. Crit Care Med 25:383–387
Opal SM (2003) Clinical trial design and outcomes in patients with severe sepsis. Shock 20(4):295–302
Opal SM, Cohen J (1999) Clinical Gram-positive sepsis: Does it fundamentally differ from Gram-negative bacterial sepsis. Crit Care Med 27:1608–1616
Bone RC (1993) Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 6:57–68
Pournaras S, Iosifidis E, Roilides E (2009) Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol 46(3):198–211
Bates DW, Pruess KE, Lee TH (1995) How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med 155:593–598
Bone RC (1994) Gram-positive organisms and sepsis. Arch Intern Med 154(1):26–34
Valles J, Leon C, Alvarez-Ledrma F (1997) Nosocomial bacteremia in critically ill patients: a multicentre study evaluating epidemiology and prognosis. Clin Infect Dis 24:403–408
Gao H, Evans TW, Finney SJ (2008) Bench-to-bedside review: sepsis, severe sepsis and septic shock-does the nature of the infecting organism matter? Crit Care 12(3):213 Epub 2008 May 6
Fisher CJ, Agosti J, Opal SM et al (1996) A phase II, double-blind, randomized, clinical trial of soluble TNF receptor:Fc fusion protein in the treatment of severe sepsis. N Engl J Med 334:1697–1702
Cross AS, Opal SM, Sadoff JD, Gemski P (1993) Choice of bacteria in animal models of sepsis. Infect Immun 61:2741–2744
Andersson J, Nagy S, Bjork L, Abrams J, Holm S, Andersson U (1992) Bacterial toxin-induced cytokine production studied at the single-cell level. Immunol Rev 127:69–96
Westendorp RGJ, Langermans JAM, Huizinga TWJ et al (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170–173
Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW (1988) Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318(12):727–732
Holmes CL, Russell JA, Walley KR (2003) Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for Therapy. Chest 124:1103–1115
Burt RA (1999) Genetics of host response to malaria. Int J Parasitol 29:973–979
Newport MJ, Huxley CM (1996) Huston S et al.: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335:1941–1949
Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV (1998) Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 338:640–644
Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Abraham E, Laterre PF, Garg R et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death: administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) study group. N Engl J Med 353(13):1332–1341
Smedira NG, Evans BH, Grais LS et al (1990) Withholding and withdrawl of life support from the critically ill. New Eng J Med. 322:309–315
Opal SM (1998) New strategies in the management of sepsis. Biomed Prog 11:52–56
Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538
Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Critical Care 14:R15
Vincent JL (1997) Dear SIRS, Im sorry to say that I don’t like you. Crit Care Med 25(2):372–374
Bossink AW, Groeneveld J, Hack CE, Thijs LG (1998) Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest 113(6):1533–1541
Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: A valid clinical entity. Crit Care Med 17:389–393
Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: a new hypothesis for the pathogenesis of the disease process. Chest 112:235–243
Rubulotta F, Marshall JC, Ramsay G, Nelson D, Levy M, Williams M (2009) Predisposition, insult/infection, response, and organ dysfunction: a new model for staging severe sepsis. Crit Care Med 37(4):1329–1335
Predicting outcome in ICU patients. 2nd European consensus conference in intensive care medicine. Intensive Care Med. (1994) 20:390–397
Vincent J, De Mendonca A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentre, prospective study. Working group on “sepsis related problems”. Crit Care Med 26:1793–1800
Opal SM, Cross AS (1999) Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13(2):285–297
Brandtzaeg P, Kerrulf P, Gaustad P et al (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204
Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347:1027–1030
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hall, T.C., Bilku, D.K., Al-Leswas, D. et al. The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis. Ir J Med Sci 181, 1–6 (2012). https://doi.org/10.1007/s11845-011-0778-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-011-0778-1